Dr. A. Sofia Cerdeira
Contact information
+44 (0)1865 221021
Colleges
Collaborators
-
Manu Vatish
Professor of Obstetrics & Consultant Obstetrician
Honours and Awards
- MFM Fellowship - 2022
- MRCOG membership - 2021
- CRN TVSM Fellowship - 2021
- HIMSS FUTURE50-Europe Class 2019
- L'Oreal-Unesco For Women in Science Award - High Commendation - 2019
- UNIVANTS of Healthcare Excellence Award - 2019
- Canon Fellowship, Canon Foundation in Europe - 2019
- HSJ Healthcare Partnership Award - 2019
- Africa Oxford Initiative Travel Grant, University of Oxford - 2018
- NIHR Academic Clinical Lectureship - 2017
- Junior Research Fellowship, Somerville College, University of Oxford - 2015
- NIHR Academic Clinical Fellowship - 2014
- Vision Grant Award, Preeclampsia Foundation, USA - 2013
- Best Data Club presentation of the year award - CVBR - Harvard University - 2012
- Excellence in Tutoring Award - Physiology, Harvard Medical School - 2012
A. Sofia Cerdeira
MD PhD
NIHR Academic Clinical Lecturer
- Lecturer in Medicine Somerville College Oxford
- MFM Fellow Queen Charlotte's and Chelsea Hospital
Research groups
L'Oreal-Unesco For Women in Science finalists
HSJ Healthcare Partnership Award
News featuring
https://www.economist.com/science-and-technology/2026/04/27/a-treatment-for-pre-eclampsia-may-be-on-the-horizon
https://www.ox.ac.uk/research/research-impact/life-saving-test-preeclampsia
https://www.thetimes.co.uk/article/new-blood-test-takes-doubt-out-of-pre-eclampsia-pp5mmv30p
https://www.bbc.co.uk/news/health-60860826
https://www.ouh.nhs.uk/news/article.aspx?id=1058
Key publications
Targeted removal of soluble Fms-like tyrosine kinase 1 in very preterm preeclampsia: a pilot trial.
Journal article
Thadhani R. et al, (2026), Nat Med
Randomized Interventional Study on Prediction of Preeclampsia/Eclampsia in Women With Suspected Preeclampsia: INSPIRE.
Journal article
Cerdeira AS. et al, (2019), Hypertension, 74, 983 - 990
Recent publications
Targeted removal of soluble Fms-like tyrosine kinase 1 in very preterm preeclampsia: a pilot trial.
Journal article
Thadhani R. et al, (2026), Nat Med
cute Presentation of Nonpuerperal Uterine Inversion Following a Diagnosis of Uterine Carcinosarcoma: A Case Report
Journal article
More AK. et al, (2026), Clinical Case Reports, 14
Considerations for gestational age, delivery indication, and therapies in preeclampsia prediction.
Journal article
Palma Dos Reis CR. et al, (2025), Am J Obstet Gynecol, 233
Predictive accuracy of sFlt-1/PlGF ratio for preeclampsia and adverse outcomes: prospective, multicenter including primary, secondary, and tertiary care institutions, observational study in Japan.
Journal article
Yamazaki T. et al, (2025), Hypertens Res, 48, 2548 - 2557
The ratio of soluble fms-like tyrosine kinase 1 to placental growth factor predicts time to delivery and mode of birth in patients with suspected preeclampsia: a secondary analysis of the INSPIRE trial.
Journal article
Palma Dos Reis CR. et al, (2025), Am J Obstet Gynecol, 232, 317.e1 - 317.e17
RESEARCH
Pre-eclampsia, angiogenic factors
I am a clinician scientist with a particular interest in pre-eclampsia and angiogenic factors. We recently conducted the first clinical trial on the use of sFlt-1/PlGF ratio in the management of patients with suspected pre-eclampsia (Cerdeira AS et al. Hypertension 2019). Data from our study and previous observations lead to the development of a protocol that is now used in clinical practice. My aim is to continue exploring the role of angiogenic factors in the prediction, diagnosis and treatment of pre-eclampsia, hopefully leading to meaningful changes in patient care.